1. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999. 353:878–882.
Article
2. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000. 11:460–466.
Article
3. van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002. 13:624–629.
Article
4. Colón-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003. 14:879–883.
Article
5. Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R. Incidence of second hip fractures. A population-based study. Osteoporos Int. 2007. 18:1279–1285.
Article
6. Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med. 2007. 167:1971–1976.
7. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995. 17:5 Suppl. 505S–511S.
Article
8. Reginster JY, Bruyere O, Audran M, et al. The Group for the Respect of Ethics and Excellence in Science. Do estrogens effectively prevent osteoporosis-related fractures? Calcif Tissue Int. 2000. 67:191–194.
Article
9. Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc. 2001. 49:1197–1204.
Article
10. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005. 80:856–861.
Article
11. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005. 21:1453–1460.
Article
12. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007. 357:1799–1809.
Article
13. Orimo H, Sugioka Y, Fukunaga H, et al. Diagnostic criteria of primary osteoporosis. Osteoporos Jpn. 1996. 4:643–643.
Article
14. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006. 367:2010–2018.
Article
15. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002. 23:570–578.
Article
16. Schnitzer T, Bone HG, Crepaldi G, et al. Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging. 2000. 12:1–12.
Article
17. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000. 82-A:1063–1070.
Article
18. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008. 19:811–818.
Article
19. Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 2009. 102:35–42.
Article
20. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002. 47:651–654.
Article
21. Heaney RP, Yates AJ, Santora AC 2nd. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res. 1997. 12:1143–1151.
Article
22. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate Osteoporosis Prevention Study Group. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab. 2000. 85:1492–1497.
Article
23. Chesnut CH 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporosis woman: effect of multiple dosage on bone mass and bone remodeling. AM J Med. 1995. 99:144–152.
Article
24. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006. 65:654–661.
Article
25. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004. 350:1189–1199.
Article
26. Magnusson HI, Lindén C, Obrant KJ, Johnell O, Karlsson MK. Bone mass changes in weight-loaded and unloaded skeletal regions following a fracture of the hip. Calcif Tissue Int. 2001. 69:78–83.
Article
27. van der Poest Clement E, van Engeland M, Ader H, Roos JC, Patka P, Lips P. Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res. 2002. 17:2247–2255.
Article
28. Weinreb M, Rodan GA, Thompson DD. Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone. 1989. 10:187–194.
Article
29. Pocock NA, Eisman JA, Yeates MG, Sambrook PN, Eberl S. Physical fitness is a major determinant of femoral neck and lumbar spine bone mineral density. J Clin Invest. 1986. 78:618–621.
Article
30. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987. 80:706–710.
Article
31. Cecilia D, Jódar E, Fernández C, Resines C, Hawkins F. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int. 2009. 20:903–910.
Article
32. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006. 119:4 Suppl 1. S12–S17.
Article
33. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003. 14:259–262.
Article
34. Hans D, Downs RW Jr, Duboeuf F, et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006. 9:15–21.
Article
35. Mounach A, Abayi DA, Ghazi M, et al. Discordance between hip and spine bone mineral density measurement using DXA: prevalence and risk factors. Semin Arthritis Rheum. 2009. 38:467–471.
Article